METTL3 and acute myeloid leukemia: In addition, previous studies have confirmed that METTL3 is precisely and differentially regulated in different tumors and organs [42–47], elucidating the mechanism underlying the abnormal overexpression of METTL3 increase during relapse or primary resistance may be a key option for targeted intervention in AML.